Cargando…

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection

Detalles Bibliográficos
Autores principales:	Fiorcari, Stefania, Atene, Claudio Giacinto, Maffei, Rossana, Debbia, Giulia, Potenza, Leonardo, Luppi, Mario, Marasca, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327720/ https://www.ncbi.nlm.nih.gov/pubmed/33691383 http://dx.doi.org/10.3324/haematol.2020.277392

Ejemplares similares

Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments
por: Fiorcari, Stefania, et al.
Publicado: (2021)

Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1
por: Fiorcari, Stefania, et al.
Publicado: (2022)

Effects of the BTN162b2 mRNA COVID‐19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2022)

Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2016)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
por: Maffei, Rossana, et al.
Publicado: (2015)

Role of Notch2 pathway in mature B cell malignancies
por: Mesini, Nicolò, et al.
Publicado: (2023)

Indoleamine 2, 3-Dioxygenase 1 Mediates Survival Signals in Chronic Lymphocytic Leukemia via Kynurenine/Aryl Hydrocarbon Receptor-Mediated MCL1 Modulation
por: Atene, Claudio Giacinto, et al.
Publicado: (2022)

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
por: Fiorcari, Stefania, et al.
Publicado: (2020)

Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia
por: Maffei, Rossana, et al.
Publicado: (2017)

The dynamic functions of IRF4 in B cell malignancies
por: Maffei, Rossana, et al.
Publicado: (2022)

An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation
por: Pozzi, Stefano, et al.
Publicado: (2022)

Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ET(A) Receptor
por: Maffei, Rossana, et al.
Publicado: (2014)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
por: Nasillo, Vincenzo, et al.
Publicado: (2022)

Pathogenetic Mechanisms of Hepatitis C Virus-Induced B-Cell Lymphomagenesis
por: Forghieri, Fabio, et al.
Publicado: (2012)

Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
por: Forghieri, Fabio, et al.
Publicado: (2018)

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges
por: Riva, Giovanni, et al.
Publicado: (2021)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
por: Puła, Bartosz, et al.
Publicado: (2019)

Bone Reconstruction in Chronic Lymphocytic Leukemia with Ibrutinib
por: Koba, Yusuke, et al.
Publicado: (2023)

The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
por: Fiorcari, Stefania, et al.
Publicado: (2013)

Acute Myeloid Leukemia in Patients Living with HIV Infection: Several Questions, Fewer Answers
por: Forghieri, Fabio, et al.
Publicado: (2020)

Hypertension in Patients Treated With Ibrutinib for Chronic Lymphocytic Leukemia
por: Roeker, Lindsey E., et al.
Publicado: (2019)

Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia
por: Kidoguchi, Keisuke, et al.
Publicado: (2021)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
por: Molica, Stefano, et al.
Publicado: (2016)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
por: Arthurs, Benjamin, et al.
Publicado: (2017)

Cutaneous mucormycosis in a chronic lymphocytic leukemia patient on ibrutinib
por: Sittig, Katherine R., et al.
Publicado: (2021)

Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
por: Liu, Yanyan, et al.
Publicado: (2022)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia
por: Shea, Lauren K., et al.
Publicado: (2017)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib
por: Okamoto, Koh, et al.
Publicado: (2016)

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
por: Landau, Dan A., et al.
Publicado: (2017)

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy
por: Voshtina, Ensi, et al.
Publicado: (2018)

Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia
por: Beresford, Rohan, et al.
Publicado: (2019)

Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia
por: Lutz, Mathias, et al.
Publicado: (2017)

Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia
por: Khan, Maliha, et al.
Publicado: (2017)

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects
por: Zhou, Hong, et al.
Publicado: (2020)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
por: Puzzolo, Maria Cristina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_46o2ae2hfooe53f0bn368c7qd6